EntreMed, Inc. is a clinical-stage biopharmaceutical company developing angiogenic therapeutics that inhibit abnormal blood vessel growth associated with a broad range of diseases, such as cancer, blindness and psoriasis. The Company has three product candidates: Endostatin, Panzem and Angiostatin, which are all in clinical trials. In addition, EntreMed has a pipeline of new proteins, small molecules, vaccines and genes-based medicines in development 

http://www.entremed.com